Pub Date : 2024-04-01Epub Date: 2024-02-07DOI: 10.1016/S2468-1253(23)00460-0
James O Lindsay, Daniel Hind, Lizzie Swaby, Hannah Berntsson, Mike Bradburn, Uday Bannur C, Jennifer Byrne, Christopher Clarke, Lauren Desoysa, Ben Dickins, Shahida Din, Richard Emsley, Gemma A Foulds, John Gribben, Christopher Hawkey, Peter M Irving, Majid Kazmi, Ellen Lee, Amanda Loban, Alan Lobo, Yashwant Mahida, Gordon W Moran, Diana Papaioannou, Miles Parkes, Andrew Peniket, A Graham Pockley, Jack Satsangi, Sreedhar Subramanian, Simon Travis, Emily Turton, Ben Uttenthal, Sergio Rutella, John A Snowden
Background: A previous controlled trial of autologous haematopoietic stem-cell transplantation (HSCT) in patients with refractory Crohn's disease did not meet its primary endpoint and reported high toxicity. We aimed to assess the safety and efficacy of HSCT with an immune-ablative regimen of reduced intensity versus standard of care in this patient population.
Methods: This open-label, multicentre, randomised controlled trial was conducted in nine National Health Service hospital trusts across the UK. Adults (aged 18-60 years) with active Crohn's disease on endoscopy (Simplified Endoscopic Score for Crohn's Disease [SES-CD] ulcer sub-score of ≥2) refractory to two or more classes of biological therapy, with no perianal or intra-abdominal sepsis or clinically significant comorbidity, were recruited. Participants were centrally randomly assigned (2:1) to either HSCT with a reduced dose of cyclophosphamide (intervention group) or standard care (control group). Randomisation was stratified by trial site by use of random permuted blocks of size 3 and 6. Patients in the intervention group underwent stem-cell mobilisation (cyclophosphamide 1 g/m2 with granulocyte colony-stimulating factor (G-CSF) 5 μg/kg) and stem-cell harvest (minimum 2·0 × 106 CD34+ cells per kg), before conditioning (fludarabine 125 mg/m2, cyclophosphamide 120 mg/kg, and rabbit anti-thymocyte globulin [thymoglobulin] 7·5 mg/kg in total) and subsequent stem-cell reinfusion supported by G-CSF. Patients in the control group continued any available conventional, biological, or nutritional therapy. The primary outcome was absence of endoscopic ulceration (SES-CD ulcer sub-score of 0) without surgery or death at week 48, analysed in the intention-to-treat population by central reading. This trial is registered with the ISRCTN registry, 17160440.
Findings: Between Oct 18, 2018, and Nov 8, 2019, 49 patients were screened for eligibility, of whom 23 (47%) were randomly assigned: 13 (57%) to the intervention group and ten (43%) to the control group. In the intervention group, ten (77%) participants underwent HSCT and nine (69%) reached 48-week follow-up; in the control group, nine (90%) reached 48-week follow-up. The trial was halted in response to nine reported suspected unexpected serious adverse reactions in six (46%) patients in the intervention group, including renal failure due to proven thrombotic microangiopathy in three participants and one death due to pulmonary veno-occlusive disease. At week 48, absence of endoscopic ulceration without surgery or death was reported in three (43%) of seven participants in the intervention group and in none of six participants in the control group with available data. Serious adverse events were more frequent in the intervention group (38 in 13 [100%] patients) than in the control group (16 in four [40%] patients). A second patient in the in
{"title":"Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial.","authors":"James O Lindsay, Daniel Hind, Lizzie Swaby, Hannah Berntsson, Mike Bradburn, Uday Bannur C, Jennifer Byrne, Christopher Clarke, Lauren Desoysa, Ben Dickins, Shahida Din, Richard Emsley, Gemma A Foulds, John Gribben, Christopher Hawkey, Peter M Irving, Majid Kazmi, Ellen Lee, Amanda Loban, Alan Lobo, Yashwant Mahida, Gordon W Moran, Diana Papaioannou, Miles Parkes, Andrew Peniket, A Graham Pockley, Jack Satsangi, Sreedhar Subramanian, Simon Travis, Emily Turton, Ben Uttenthal, Sergio Rutella, John A Snowden","doi":"10.1016/S2468-1253(23)00460-0","DOIUrl":"10.1016/S2468-1253(23)00460-0","url":null,"abstract":"<p><strong>Background: </strong>A previous controlled trial of autologous haematopoietic stem-cell transplantation (HSCT) in patients with refractory Crohn's disease did not meet its primary endpoint and reported high toxicity. We aimed to assess the safety and efficacy of HSCT with an immune-ablative regimen of reduced intensity versus standard of care in this patient population.</p><p><strong>Methods: </strong>This open-label, multicentre, randomised controlled trial was conducted in nine National Health Service hospital trusts across the UK. Adults (aged 18-60 years) with active Crohn's disease on endoscopy (Simplified Endoscopic Score for Crohn's Disease [SES-CD] ulcer sub-score of ≥2) refractory to two or more classes of biological therapy, with no perianal or intra-abdominal sepsis or clinically significant comorbidity, were recruited. Participants were centrally randomly assigned (2:1) to either HSCT with a reduced dose of cyclophosphamide (intervention group) or standard care (control group). Randomisation was stratified by trial site by use of random permuted blocks of size 3 and 6. Patients in the intervention group underwent stem-cell mobilisation (cyclophosphamide 1 g/m<sup>2</sup> with granulocyte colony-stimulating factor (G-CSF) 5 μg/kg) and stem-cell harvest (minimum 2·0 × 10<sup>6</sup> CD34<sup>+</sup> cells per kg), before conditioning (fludarabine 125 mg/m<sup>2</sup>, cyclophosphamide 120 mg/kg, and rabbit anti-thymocyte globulin [thymoglobulin] 7·5 mg/kg in total) and subsequent stem-cell reinfusion supported by G-CSF. Patients in the control group continued any available conventional, biological, or nutritional therapy. The primary outcome was absence of endoscopic ulceration (SES-CD ulcer sub-score of 0) without surgery or death at week 48, analysed in the intention-to-treat population by central reading. This trial is registered with the ISRCTN registry, 17160440.</p><p><strong>Findings: </strong>Between Oct 18, 2018, and Nov 8, 2019, 49 patients were screened for eligibility, of whom 23 (47%) were randomly assigned: 13 (57%) to the intervention group and ten (43%) to the control group. In the intervention group, ten (77%) participants underwent HSCT and nine (69%) reached 48-week follow-up; in the control group, nine (90%) reached 48-week follow-up. The trial was halted in response to nine reported suspected unexpected serious adverse reactions in six (46%) patients in the intervention group, including renal failure due to proven thrombotic microangiopathy in three participants and one death due to pulmonary veno-occlusive disease. At week 48, absence of endoscopic ulceration without surgery or death was reported in three (43%) of seven participants in the intervention group and in none of six participants in the control group with available data. Serious adverse events were more frequent in the intervention group (38 in 13 [100%] patients) than in the control group (16 in four [40%] patients). A second patient in the in","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":null,"pages":null},"PeriodicalIF":35.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139716619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01Epub Date: 2024-02-13DOI: 10.1016/S2468-1253(23)00454-5
Thomas Yau, Ahmed Kaseb, Ann-Lii Cheng, Shukui Qin, Andrew X Zhu, Stephen L Chan, Tamar Melkadze, Wattana Sukeepaisarnjaroen, Valery Breder, Gontran Verset, Edward Gane, Ivan Borbath, Jose David Gomez Rangel, Baek-Yeol Ryoo, Tamta Makharadze, Philippe Merle, Fawzi Benzaghou, Steven Milwee, Zhong Wang, Dominic Curran, Robin Kate Kelley, Lorenza Rimassa
Background: The aim of the COSMIC-312 trial was to evaluate cabozantinib plus atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma. In the initial analysis, cabozantinib plus atezolizumab significantly prolonged progression-free survival versus sorafenib. Here, we report the pre-planned final overall survival analysis and updated safety and efficacy results following longer follow-up.
Methods: COSMIC-312 was an open-label, randomised, phase 3 study done across 178 centres in 32 countries. Patients aged 18 years or older with previously untreated advanced hepatocellular carcinoma were eligible. Patients must have had measurable disease per Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1), and adequate marrow and organ function, including Child-Pugh class A liver function; those with fibrolamellar carcinoma, sarcomatoid hepatocellular carcinoma, or combined hepatocellular cholangiocarcinoma were ineligible. Patients were randomly assigned (2:1:1) using a web-based interactive response system to a combination of oral cabozantinib 40 mg once daily plus intravenous atezolizumab 1200 mg every 3 weeks, oral sorafenib 400 mg twice daily, or oral single-agent cabozantinib 60 mg once daily. Randomisation was stratified by disease aetiology, geographical region, and presence of extrahepatic disease or macrovascular invasion. Dual primary endpoints were for cabozantinib plus atezolizumab versus sorafenib: progression-free survival per RECIST 1.1, as assessed by a blinded independent radiology committee, in the first 372 randomly assigned patients (previously reported) and overall survival in all patients randomly assigned to cabozantinib plus atezolizumab or sorafenib. The secondary endpoint was progression-free survival in all patients randomly assigned to cabozantinib versus sorafenib. Outcomes in all randomly assigned patients, including final overall survival, are presented. Safety was assessed in all randomly assigned patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT03755791.
Findings: Between Dec 7, 2018, and Aug 27, 2020, 432 patients were randomly assigned to combination treatment, 217 to sorafenib, and 188 to single-agent cabozantinib, and included in all efficacy analyses. 704 (84%) patients were male and 133 (16%) were female. 824 of these patients received at least one dose of study treatment and were included in the safety population. Median follow-up was 22·1 months (IQR 19·3-24·8). Median overall survival was 16·5 months (96% CI 14·5-18·7) for the combination treatment group and 15·5 months (12·2-20·0) for the sorafenib group (hazard ratio [HR] 0·98 [0·78-1·24]; stratified log-rank p=0·87). Median progression-free survival was 6·9 months (99% CI 5·7-8·2) for the combination treatment group, 4·3 months (2·9-6·1) for the sorafenib group, and 5·8 months
研究背景COSMIC-312试验的目的是评估卡博替尼加阿特珠单抗与索拉非尼在既往未经治疗的晚期肝细胞癌患者中的疗效。在初步分析中,卡博替尼加阿特珠单抗与索拉非尼相比,无进展生存期明显延长。在此,我们报告了预先计划的最终总生存期分析以及更长时间随访后的最新安全性和有效性结果:COSMIC-312是一项开放标签、随机的3期研究,在32个国家的178个中心进行。年龄在18岁或18岁以上、既往未接受过治疗的晚期肝细胞癌患者均符合条件。根据《实体瘤反应评估标准1.1版》(RECIST 1.1),患者必须患有可测量的疾病,且骨髓和器官功能正常,包括Child-Pugh A级肝功能;患有纤维母细胞瘤、肉瘤样肝细胞癌或合并肝细胞胆管癌的患者不符合条件。患者通过网络互动应答系统被随机分配(2:1:1)到口服卡博替尼40毫克、每天一次加静脉注射atezolizumab 1200毫克(每3周一次)、口服索拉非尼400毫克、每天两次或口服单药卡博替尼60毫克、每天一次的组合方案中。随机分组按疾病病因、地理区域、是否存在肝外疾病或大血管侵犯等因素进行。卡博替尼加阿特珠单抗与索拉非尼的双重主要终点是:前372名随机分配患者的无进展生存期(RECIST 1.1标准,由独立的放射学盲法委员会评估)(之前已有报道),以及所有随机分配到卡博替尼加阿特珠单抗或索拉非尼的患者的总生存期。次要终点是随机分配到卡博替尼和索拉非尼的所有患者的无进展生存期。本文介绍了所有随机分配患者的结果,包括最终总生存期。对所有随机分配且至少接受过一次药物治疗的患者进行了安全性评估。该试验已在 ClinicalTrials.gov 注册,编号为 NCT03755791:2018年12月7日至2020年8月27日期间,432名患者被随机分配接受联合治疗,217名患者接受索拉非尼治疗,188名患者接受单药卡博赞替尼治疗,并纳入所有疗效分析。704例(84%)患者为男性,133例(16%)为女性。其中824名患者接受了至少一个剂量的研究治疗,并被纳入安全性研究人群。中位随访时间为 22-1 个月(IQR 19-3-24-8)。联合治疗组的中位总生存期为16-5个月(96% CI 14-5-18-7),索拉非尼组为15-5个月(12-2-20-0)(危险比[HR] 0-98 [0-78-1-24];分层对数秩p=0-87)。联合治疗组的中位无进展生存期为6-9个月(99% CI 5-7-8-2),索拉非尼组为4-3个月(2-9-6-1),单药卡博替尼组为5-8个月(99% CI 5-4-8-2)(联合治疗与索拉非尼相比,HR 0-74 [0-56-0-97] ;单药卡博替尼与索拉非尼相比,HR 0-78 [99% CI 0-56-1-09],P=0-05)。联合治疗组 429 例患者中有 281 例(66%)、索拉非尼组 207 例患者中有 100 例(48%)、卡博赞替尼单药组 188 例患者中有 108 例(57%)发生了 3 级或 4 级不良事件;最常见的不良反应是高血压(37 [9%] vs 17 [8%] vs 23 [12%])、掌跖红斑性肢痛症(36 [8%] vs 18 [9%] vs 16 [9%])、天冬氨酸氨基转移酶升高(42 [10%] vs 8 [4%] vs 17 [9%])和丙氨酸氨基转移酶升高(40 [9%] vs 6 [3%] vs 13 [7%])。223例(52%)联合治疗组患者、84例(41%)索拉非尼组患者和87例(46%)单药卡博赞替尼组患者发生了严重不良事件。联合治疗组有6例(1%)患者发生治疗相关死亡(脑病、肝功能衰竭、药物性肝损伤、食道静脉曲张出血、多器官功能障碍综合征和肿瘤溶解综合征),单药组有1例(解释......)死亡(解释......):在晚期肝细胞癌患者中,一线卡博替尼加阿特珠单抗与索拉非尼相比并不能改善总生存期。与索拉非尼相比,联合用药的无进展生存期优势得以保持,且未出现新的安全性信号:资金来源:Exelixis 和益普生。
{"title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.","authors":"Thomas Yau, Ahmed Kaseb, Ann-Lii Cheng, Shukui Qin, Andrew X Zhu, Stephen L Chan, Tamar Melkadze, Wattana Sukeepaisarnjaroen, Valery Breder, Gontran Verset, Edward Gane, Ivan Borbath, Jose David Gomez Rangel, Baek-Yeol Ryoo, Tamta Makharadze, Philippe Merle, Fawzi Benzaghou, Steven Milwee, Zhong Wang, Dominic Curran, Robin Kate Kelley, Lorenza Rimassa","doi":"10.1016/S2468-1253(23)00454-5","DOIUrl":"10.1016/S2468-1253(23)00454-5","url":null,"abstract":"<p><strong>Background: </strong>The aim of the COSMIC-312 trial was to evaluate cabozantinib plus atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma. In the initial analysis, cabozantinib plus atezolizumab significantly prolonged progression-free survival versus sorafenib. Here, we report the pre-planned final overall survival analysis and updated safety and efficacy results following longer follow-up.</p><p><strong>Methods: </strong>COSMIC-312 was an open-label, randomised, phase 3 study done across 178 centres in 32 countries. Patients aged 18 years or older with previously untreated advanced hepatocellular carcinoma were eligible. Patients must have had measurable disease per Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1), and adequate marrow and organ function, including Child-Pugh class A liver function; those with fibrolamellar carcinoma, sarcomatoid hepatocellular carcinoma, or combined hepatocellular cholangiocarcinoma were ineligible. Patients were randomly assigned (2:1:1) using a web-based interactive response system to a combination of oral cabozantinib 40 mg once daily plus intravenous atezolizumab 1200 mg every 3 weeks, oral sorafenib 400 mg twice daily, or oral single-agent cabozantinib 60 mg once daily. Randomisation was stratified by disease aetiology, geographical region, and presence of extrahepatic disease or macrovascular invasion. Dual primary endpoints were for cabozantinib plus atezolizumab versus sorafenib: progression-free survival per RECIST 1.1, as assessed by a blinded independent radiology committee, in the first 372 randomly assigned patients (previously reported) and overall survival in all patients randomly assigned to cabozantinib plus atezolizumab or sorafenib. The secondary endpoint was progression-free survival in all patients randomly assigned to cabozantinib versus sorafenib. Outcomes in all randomly assigned patients, including final overall survival, are presented. Safety was assessed in all randomly assigned patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT03755791.</p><p><strong>Findings: </strong>Between Dec 7, 2018, and Aug 27, 2020, 432 patients were randomly assigned to combination treatment, 217 to sorafenib, and 188 to single-agent cabozantinib, and included in all efficacy analyses. 704 (84%) patients were male and 133 (16%) were female. 824 of these patients received at least one dose of study treatment and were included in the safety population. Median follow-up was 22·1 months (IQR 19·3-24·8). Median overall survival was 16·5 months (96% CI 14·5-18·7) for the combination treatment group and 15·5 months (12·2-20·0) for the sorafenib group (hazard ratio [HR] 0·98 [0·78-1·24]; stratified log-rank p=0·87). Median progression-free survival was 6·9 months (99% CI 5·7-8·2) for the combination treatment group, 4·3 months (2·9-6·1) for the sorafenib group, and 5·8 months ","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":null,"pages":null},"PeriodicalIF":35.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139747811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01Epub Date: 2024-02-13DOI: 10.1016/S2468-1253(24)00007-4
Anna Saborowski, Ana Lleo
{"title":"The COSMIC-312 study: will it shape future combination therapies for advanced hepatocellular carcinoma?","authors":"Anna Saborowski, Ana Lleo","doi":"10.1016/S2468-1253(24)00007-4","DOIUrl":"10.1016/S2468-1253(24)00007-4","url":null,"abstract":"","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":null,"pages":null},"PeriodicalIF":35.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139747812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01Epub Date: 2024-02-07DOI: 10.1016/S2468-1253(24)00004-9
Rachele Ciccocioppo, Ludovit Gaspar
{"title":"Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere.","authors":"Rachele Ciccocioppo, Ludovit Gaspar","doi":"10.1016/S2468-1253(24)00004-9","DOIUrl":"10.1016/S2468-1253(24)00004-9","url":null,"abstract":"","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":null,"pages":null},"PeriodicalIF":35.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139716618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01Epub Date: 2024-02-07DOI: 10.1016/S2468-1253(24)00039-6
The Editors Of The Lancet Gastroenterology Hepatology
{"title":"Expression of concern-Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre randomised controlled trial.","authors":"The Editors Of The Lancet Gastroenterology Hepatology","doi":"10.1016/S2468-1253(24)00039-6","DOIUrl":"10.1016/S2468-1253(24)00039-6","url":null,"abstract":"","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":null,"pages":null},"PeriodicalIF":35.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139716617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-13DOI: 10.1016/s2468-1253(24)00043-8
Raghav Sundar, Elizabeth C Smyth
{"title":"Inconsistencies in the predictive value of PD-L1 in metastatic gastroesophageal cancer","authors":"Raghav Sundar, Elizabeth C Smyth","doi":"10.1016/s2468-1253(24)00043-8","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00043-8","url":null,"abstract":"","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":null,"pages":null},"PeriodicalIF":35.7,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140136037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-06DOI: 10.1016/s2468-1253(23)00444-2
Maurizio Mennini, Federica Ferrari, Pasquale Parisi, Giovanni Di Nardo
{"title":"Gluten and non-coeliac gluten sensitivity: the nocebo effect and future avenues","authors":"Maurizio Mennini, Federica Ferrari, Pasquale Parisi, Giovanni Di Nardo","doi":"10.1016/s2468-1253(23)00444-2","DOIUrl":"https://doi.org/10.1016/s2468-1253(23)00444-2","url":null,"abstract":"","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":null,"pages":null},"PeriodicalIF":35.7,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140067579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-06DOI: 10.1016/s2468-1253(24)00052-9
J, o, e, , M, o, o, d, y
{"title":"Infinite Life","authors":"J, o, e, , M, o, o, d, y","doi":"10.1016/s2468-1253(24)00052-9","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00052-9","url":null,"abstract":"","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":null,"pages":null},"PeriodicalIF":35.7,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140067613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-06DOI: 10.1016/s2468-1253(24)00016-5
Ji Young Bang, Shyam Varadarajulu
{"title":"The DESTIN trial: to step up or not? – Authors' reply","authors":"Ji Young Bang, Shyam Varadarajulu","doi":"10.1016/s2468-1253(24)00016-5","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00016-5","url":null,"abstract":"","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":null,"pages":null},"PeriodicalIF":35.7,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140067741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}